UroGen’s urothelial cancer drug hits target, could prevent surgeryFormer Novartis oncology chief Liz Barrett’s decision to jump ship to lead the biotech UroGen appears to have Share XUroGen’s urothelial cancer drug hits target, could prevent surgeryhttps://pharmaphorum.com/news/urogens-urothelial-cancer-drug-hits-target-could-prevent-surgery/
UroGen appoints former Novartis cancer chief Barrett as CEONovartis’ former oncology CEO Liz Barrett has left to join a little known biotech, UroGen, to help bring Share XUroGen appoints former Novartis cancer chief Barrett as CEOhttps://pharmaphorum.com/news/urogen-appoints-former-novartis-cancer-chief-barrett-as-ceo/
